153 related articles for article (PubMed ID: 37081791)
1. Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR.
Tan D; Jiang W; Hu R; Li Z; Ou T
Cancer Med; 2023 May; 12(10):11503-11512. PubMed ID: 37081791
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
3. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
4. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
Borkowska EM; Traczyk-Borszyńska M; Kutwin P; Pietrusiński M; Jabłonowski Z; Borowiec M
Urol Oncol; 2019 Dec; 37(12):907-915. PubMed ID: 31377167
[TBL] [Abstract][Full Text] [Related]
8. Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
Baxter L; Gordon NS; Ott S; Wang J; Patel P; Goel A; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; ; Bryan RT; Ward DG
Sci Rep; 2023 Jan; 13(1):1060. PubMed ID: 36658180
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
10. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
Roperch JP; Hennion C
BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
[TBL] [Abstract][Full Text] [Related]
11. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N
Front Oncol; 2020; 10():755. PubMed ID: 32509577
[TBL] [Abstract][Full Text] [Related]
13. ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques.
Machnicki MM; Glodkowska-Mrowka E; Lewandowski T; Ploski R; Wlodarski P; Stoklosa T
Acta Biochim Pol; 2013; 60(1):57-64. PubMed ID: 23460942
[TBL] [Abstract][Full Text] [Related]
14. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
Luo Y; Li Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
[TBL] [Abstract][Full Text] [Related]
15. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
[TBL] [Abstract][Full Text] [Related]
16. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations.
Yu PC; Tan LC; Zhu XL; Shi X; Chernikov R; Semenov A; Zhang L; Ma B; Wang Y; Zhou XY; Ji QH; Wei WJ; Wang YL
Endocr Pract; 2021 Jul; 27(7):698-705. PubMed ID: 33515759
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
18. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
19. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
20. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
